Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Vaccine Boosters for SARS-CoV-2 Variants
NCT04927065Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- May 2021
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of mRNA-1273.211, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, elasomeran + imelasomeran and 3 more in coronavirus disease 2019 (COVID-19) (14 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions, Number of Participants With Unsolicited Adverse Events and 4 more. Started May 2021; status: completed.
02
Drugs
mRNA-1273.211mRNA-1273.617.2mRNA-1273.213mRNA-1273.529elasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04927065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927065.